Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammation Eye Pain Clear all
Completed Phase 3 Interventional Results available

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192150
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192137
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT06128369
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Glendale, California • Inglewood, California • Newport Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01298752
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

NCT01367249
View directory record Official record
Conditions
Pain, Inflammation, Cataract
Interventions
Bromfenac Ophthalmic Solution, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01591161
View directory record Official record
Conditions
Cataract, Inflammation, Surgery
Interventions
Mapracorat, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed No phase listed Observational

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971
View directory record Official record
Conditions
Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Nicole Fram M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

NCT04781335
View directory record Official record
Conditions
Cataract
Interventions
Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Drug
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
40 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 1 Interventional Results available

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

NCT01605942
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Drug Delivery System, Placebo Drug Delivery System
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

NCT04168112
View directory record Official record
Conditions
Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
Interventions
Dextenza, Prednisolone Acetate
Drug
Lead sponsor
Sight Medical Doctors PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Babylon, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

NCT03499873
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac 0.3% Oph Susp, Placebos, Nepafenac 0.3% Oph Susp (reference)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01996839
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID), Vehicle (TID)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

NCT00853970
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Bromfenac Ophthalmic Solution, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

NCT00333918
View directory record Official record
Conditions
Pain, Inflammation
Interventions
bromfenac ophthalmic solution, placebo comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

NCT04739709
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

Confirmatory Study Nepafenac 0.3%

NCT01109173
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle, NEVANAC Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
2,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02786901
View directory record Official record
Conditions
Cataract, Pain, Ocular Inflammation
Interventions
Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 6, 2026, 8:04 AM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 6, 2026, 8:04 AM EDT